APHERESIS is now a common therapeutic modality, with proven clinical benefits for several gastrointestinal disorders including inflammatory bowel disease (IBD), 1 pouchitis, intestinal Bechét's ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
Bendamustine treatment before apheresis is known to reduce survival in large B-cell lymphoma (LBCL) patients receiving chimeric antigen receptor (CAR) T-cell therapy. Bendamustine has been shown to ...
When the Red Cross has an emergency, Warren Betts answers the call. He recently put himself on the front line in response to the organization's emergency appeal for blood donors. His quick reaction is ...
With long COVID patients becoming increasingly frustrated with the lack of available treatments, some have now taken to traveling to Cyprus, Germany, and Switzerland for experimental "blood washing," ...
Data indicate that the AutoCell platform could pave the way for CGTs for the first time as first-line therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results